Whole cell vaccine, without exogenous antigen-presenting cell
| Disease . | Vaccine . | N . | Immune response . | Clinical response . | Reference . |
|---|---|---|---|---|---|
| AML/MDS | GVAX administered following allogeneic transplantation | 15 patients vaccinated | Local vaccine site reaction, biopsy demonstrating T-cell infiltrate. | 2-y OS for patients who received at least 1 vaccine was 57% ± 14% | 55 |
| Decrease in soluble MICA and MICB in clinical responders. | |||||
| CLL | GVAX administered following allogeneic transplantation | 18 patients vaccinated | Interferon γ secretion by CD8 T cells isolated from vaccinated patients after exposure to autologous tumor. | Estimated 2-y PFS in vaccinated patients: 82% | 56 |
| In 4 patients, it was shown that 17% of CD8+ T-cell clones reacted against CLL antigens. | Estimated 2-y OS in vaccinated patients: 88% | ||||
| Multiple myeloma | GVAX administered following autologous transplant | 28 patients vaccinated | Injection site reactions in all patients 41% of patients who received at least 4 posttransplant vaccines demonstrated increase in T-cell secretion of interferon γ secretion after ex vivo stimulation. | 3-y PFS in 28 patients treated with vaccine was 61.8%; 3-y OS was 73.7% | 57 |
| Disease . | Vaccine . | N . | Immune response . | Clinical response . | Reference . |
|---|---|---|---|---|---|
| AML/MDS | GVAX administered following allogeneic transplantation | 15 patients vaccinated | Local vaccine site reaction, biopsy demonstrating T-cell infiltrate. | 2-y OS for patients who received at least 1 vaccine was 57% ± 14% | 55 |
| Decrease in soluble MICA and MICB in clinical responders. | |||||
| CLL | GVAX administered following allogeneic transplantation | 18 patients vaccinated | Interferon γ secretion by CD8 T cells isolated from vaccinated patients after exposure to autologous tumor. | Estimated 2-y PFS in vaccinated patients: 82% | 56 |
| In 4 patients, it was shown that 17% of CD8+ T-cell clones reacted against CLL antigens. | Estimated 2-y OS in vaccinated patients: 88% | ||||
| Multiple myeloma | GVAX administered following autologous transplant | 28 patients vaccinated | Injection site reactions in all patients 41% of patients who received at least 4 posttransplant vaccines demonstrated increase in T-cell secretion of interferon γ secretion after ex vivo stimulation. | 3-y PFS in 28 patients treated with vaccine was 61.8%; 3-y OS was 73.7% | 57 |
CLL, chronic lymphocytic leukemia; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B. Other abbreviations are explained in Table 1.